Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 13/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.54 |
| ▸ | HRH1 | P35367 | 4/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.54 |
| ▸ | HTR1A | P08908 | 3/20 | 0.54 |
| ▸ | HRH2 | P25021 | 3/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | HTR1B | P28222 | 1/20 | 0.54 |
| ▸ | HTR1E | P28566 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.51 |
| ▸ | GRM5 | P41594 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589773 | 0.88 | MEN1 (0.55) | TMEM97SIGMAR1HRH1HRH3HTR1A | |
| SCHEMBL2384619 | 0.84 | DRD2 (0.59) | TMEM97SIGMAR1HRH1HRH3HTR1A | |
| SCHEMBL4014464 | 0.84 | MAPT (0.49) | HTR1AHTR2AGRM5MEN1KMT2A | |
| SCHEMBL9727540 | 0.84 | NPSR1 (0.68) | TMEM97SIGMAR1HRH1HRH3HTR1A | |
| SCHEMBL27208439 | 0.83 | TMEM97 (0.58) | TMEM97SIGMAR1HRH1HRH3HTR1A | |
| SCHEMBL13006305 | 0.82 | TMEM97 (0.55) | TMEM97SIGMAR1HRH1HRH3HTR1A | |
| SCHEMBL21591697 | 0.82 | TMEM97 (0.55) | TMEM97SIGMAR1HRH1HRH3HTR1A | |
| SCHEMBL15487005 | 0.82 | GRM5 (0.51) | TMEM97SIGMAR1HRH1HRH3HTR1A | |
| SCHEMBL13006300 | 0.82 | TMEM97 (0.57) | TMEM97SIGMAR1HRH1HRH3HTR1A | |
| SCHEMBL5669206 | 0.81 | TMEM97 (0.58) | TMEM97SIGMAR1HRH1HRH3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220041597-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
| US-20220041597-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
| EP-3902533-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | Forma Therapeutics, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| WO-2020139916-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2074127-A1 | PYRAZOLO [1, 5-A]PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008037459-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008037459-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041597-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | MCL1, HSPA9, USP10 | TMEM97 3375/4885SIGMAR1 4066/4885HRH1 4361/4885 |
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | TMEM97 3981/4885SIGMAR1 4220/4885HRH1 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.